Japan Insomnia Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Type (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, and Others), By Sales Channel (Prescription and Over-the-Counter (OTC)), and Japan Insomnia Therapeutics Market Insights, Industry Trend, Forecasts to 2035.

Japan Insomnia Therapeutics Market Insights Forecasts to 2035

• The Japan Insomnia Therapeutics Market Size Was Estimated at USD 78.2 million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 6.44% from 2025 to 2035
• The Japan Insomnia Therapeutics Market Size is Expected to Reach USD 155.4 million by 2035

According to a research report published by Spherical Insights & Consulting, the Insomnia Therapeutics market is anticipated to reach USD 155.4 million by 2035, growing at a CAGR of 6.44% from 2025 to 2035. The Japan insomnia therapeutics market is driven by various factors, including rising stress levels, lifestyle changes, a growing geriatric population, rising awareness about sleep disorders and advancements in treatment options.

Market Overview

The Japan insomnia therapeutics market focuses on the development, production, distribution, and use of treatments for managing insomnia. Insomnia is one of the most prevalent sleep disorders, characterized by difficulty in falling asleep, maintaining sleep, or waking up too early and not being able to go back to sleep. Insomnia is classified as an acute and chronic condition. Therapeutics for insomnia include benzodiazepines, nonbenzodiazepines, antidepressants, orexin antagonists, and melatonin antagonists. Japan's rapidly aging population has higher rates of insomnia based on changes in sleep patterns with increasing age and comorbidities is a key driver for this market. Changing lifestyle leads to high stress and mental health problems, which lead to sleep disorders, which further creates the demand for effective medications for the management of insomnia. The rising awareness about sleep health presents an opportunity for innovative and accessible treatments.

Report Coverage

This research report categorizes the market for the Japan insomnia therapeutics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan insomnia therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan insomnia therapeutics market.

Driving Factors

The growth of Japan insomnia therapeutics market is primarily fueled by the increased prevalence of sleep-related disorders among working professionals and younger people, which has increased the demand for effective therapies. Japan’s rapidly aging population, with a high prevalence of sleep disturbances, significantly drives the demand for effective insomnia therapeutics tailored to older adults. Additionally, enhanced diagnostic tools and greater awareness play an important role in the market expansion.

Restraining Factors

One of the limitations is social stigma towards sleep disorders and mental illness, which generally deters people from going to experts for advice. Additionally, side effects associated with long-term use of sedative medications reduced patient adherence and trust.

Market Segmentation

The Japan insomnia therapeutics market share is classified into type and sales channel.

• The benzodiazepines segment held a dominant share of the market in 2024 and is expected to grow at a rapid CAGR during the forecast period.

The Japan insomnia therapeutics market is segmented by type into benzodiazepines, nonbenzodiazepines, antidepressants, orexin antagonists, melatonin antagonists, and others. Among these, the benzodiazepines segment held a dominant share in 2024 and is expected to grow at a rapid CAGR during the forecast period. This is due to its usefulness for insomnia associated with acute stress. Additionally, they are highly accepted by physicians due to their quick results.

• The over-the-counter (OTC) segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan insomnia therapeutics market is segmented by sales channel into prescription and over-the-counter (OTC). Among these, the over-the-counter (OTC) segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the increasing number of patients with insomnia. Additionally, they does not require prescription hence they are easily available to patient.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan insomnia therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Takeda Pharmaceutical Company Limited
• Sumitomo Pharma Co., Ltd.
• Shionogi & Co., Ltd.
• Eisai Co., Ltd.
• Others

Recent Developments

• In September 2024, Nxera Pharma received approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan insomnia therapeutics market based on the below-mentioned segments:

Japan Insomnia Therapeutics Market, By Type

• Benzodiazepines
• Nonbenzodiazepines
• Antidepressants
• Orexin Antagonists
• Melatonin Antagonists
• Others

Japan Insomnia Therapeutics Market, By Sales Channel

• Prescription
• Over-the-Counter (OTC)